Chen Qun, Moghaddas Shadi, Hoppel Charles L, Lesnefsky Edward J
Department of Medicine, Division of Cardiology, School of Medicine, Case Western Reserve University, Cleveland, Ohio, USA.
J Pharmacol Exp Ther. 2006 Dec;319(3):1405-12. doi: 10.1124/jpet.106.110262. Epub 2006 Sep 21.
Cardiac mitochondria sustain damage during ischemia and reperfusion, contributing to cell death. The reversible blockade of electron transport during ischemia with amobarbital, an inhibitor at the rotenone site of complex I, protects mitochondria against ischemic damage. Amobarbital treatment immediately before ischemia was used to test the hypothesis that damage to mitochondrial respiration occurs mainly during ischemia and that protection of mitochondria during ischemia leads to decreased cardiac injury with reperfusion. Langendorff-perfused Fischer-344 rat hearts were treated with amobarbital (2.5 mM) or vehicle for 1 min immediately before 25 min of global ischemia. Both groups were reperfused for 30 min without additional treatment. Subsarcolemmal (SSM) and interfibrillar (IFM) populations of mitochondria were isolated after reperfusion. Ischemia and reperfusion decreased state 3 and increased state 4 respiration rate in both SSM and IFM. Amobarbital treatment protected oxidative phosphorylation measured following reperfusion and improved the coupling of respiration. Cytochrome c content measured in SSM and IFM following reperfusion decreased in untreated, but not in amobarbital-treated, hearts. H(2)O(2) release from SSM and IFM isolated from amobarbital-treated hearts during reperfusion was markedly decreased. Amobarbital treatment before ischemia improved recovery of contractile function (percentage of preischemic developed pressure: untreated 51 +/- 4%, n = 12; amobarbital 70 +/- 4%, n = 11, p < 0.01) and substantially reduced infarct size (untreated 32 +/- 2%, n = 7; amobarbital 13 +/- 2%, n = 7, p < 0.01). Thus, mitochondrial damage occurs mainly during ischemia rather than during reperfusion. Reperfusion in the setting of preserved mitochondrial respiratory function attenuates the mitochondrial release of reactive oxygen species, enhances contractile recovery, and decreases myocardial infarct size.
心脏线粒体在缺血和再灌注期间会持续受损,从而导致细胞死亡。用异戊巴比妥(一种复合体I鱼藤酮位点的抑制剂)在缺血期间可逆性阻断电子传递,可保护线粒体免受缺血损伤。在缺血前立即使用异戊巴比妥治疗,以检验以下假设:线粒体呼吸损伤主要发生在缺血期间,并且缺血期间对线粒体的保护会导致再灌注时心脏损伤减轻。在25分钟全心缺血前,用异戊巴比妥(2.5 mM)或赋形剂对Langendorff灌注的Fischer-344大鼠心脏治疗1分钟。两组均在无额外治疗的情况下再灌注30分钟。再灌注后分离出肌膜下(SSM)和肌原纤维间(IFM)的线粒体群体。缺血和再灌注降低了SSM和IFM的状态3呼吸,并提高了状态4呼吸速率。异戊巴比妥治疗可保护再灌注后测得的氧化磷酸化,并改善呼吸偶联。再灌注后在SSM和IFM中测得的细胞色素c含量在未治疗的心脏中降低,但在异戊巴比妥治疗的心脏中未降低。再灌注期间,从异戊巴比妥治疗的心脏中分离出的SSM和IFM释放的H(2)O(2)明显减少。缺血前的异戊巴比妥治疗改善了收缩功能的恢复(缺血前发展压力的百分比:未治疗组51±4%,n = 12;异戊巴比妥组70±4%,n = 11,p < 0.01),并显著减小了梗死面积(未治疗组32±2%,n = 7;异戊巴比妥组13±2%,n = 7,p < 0.01)。因此,线粒体损伤主要发生在缺血期间而非再灌注期间。在保留线粒体呼吸功能的情况下进行再灌注,可减少线粒体活性氧的释放,增强收缩恢复,并减小心肌梗死面积。